Henlius Has First ‘China-Developed’ Biosimilar Accepted For EMA Review

 
• By Penelope MacRae

European regulators have accepted for review a marketing authorization application for the first ‘China-developed’ biosimilar, a version of Roche’s blockbuster breast-cancer drug Herceptin (trastuzumab) developed by Chinese biotech firm Henlius.

China_EU_Flags
Henlius is boasting the first China-developed biosimilar to be accepted for review by the EMA • Source: Shutterstock

More from Biosimilars

More from Products